Use of Lozenges Containing Lactobacillus brevis CD2 in Recurrent Aphthous Stomatitis: A Double-Blind Placebo-Controlled Trial

Table 2

E Summary of laboratory parameters before and after administration of Lactobacillus Brevis CD2 or placebo lozenges.

		L. brevis CD2	Placebo	Intergroup comparison
Nitrite/Nitrate (μM)	(T0)	42.38 ± 4,58	39.76 ± 5.08	𝑃=.14
	(T1)	7.5 ± 1.5	27.5 ± 3.5	𝑃<.01
PGE2 (ng ml^−1)	(T0)	1.89 ± 0.2	1.77 ± 0.2	𝑃=.11
	(T1)	0.40 ± 0.05	1.02 ± 0.3	𝑃<.01
IFNγ (pg ml^−1)	(T0)	32.25 ± 4.2	30.85 ± 4.2	𝑃=.36
	(T1)	9.57 ± 1.7	21.07 ± 2.9	𝑃<.01

T0: before treatment; T1: after treatment.